Pillsbury Lake Capital LLC Takes Position in MiMedx Group, Inc $MDXG

Pillsbury Lake Capital LLC bought a new stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 215,239 shares of the company’s stock, valued at approximately $828,670,000. Pillsbury Lake Capital LLC owned about 0.15% of MiMedx Group as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Sunbelt Securities Inc. bought a new position in MiMedx Group during the first quarter valued at $42,000. E Fund Management Co. Ltd. purchased a new stake in MiMedx Group in the 2nd quarter worth about $45,000. Legal & General Group Plc bought a new stake in MiMedx Group in the second quarter worth about $45,000. Kemnay Advisory Services Inc. bought a new position in shares of MiMedx Group during the fourth quarter valued at approximately $48,000. Finally, Williams & Novak LLC purchased a new stake in shares of MiMedx Group in the second quarter worth approximately $53,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Raymond James Financial set a $8.00 price objective on MiMedx Group in a research report on Monday, August 17th. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Citizens Jmp lowered their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Finally, Seaport Research Partners lowered shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.43.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $4.42 on Thursday. The business has a fifty day moving average of $4.15 and a 200 day moving average of $4.10. MiMedx Group, Inc has a 1 year low of $3.03 and a 1 year high of $7.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The firm has a market capitalization of $644.26 million, a price-to-earnings ratio of 110.53 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The business had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. As a group, research analysts expect that MiMedx Group, Inc will post -0.1 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.